Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

For Recurrent or Stage 4 Head and Neck Cancer, Immunotherapy as 1st-Line Treatment Prolongs Survival

For Recurrent or Stage 4 Head and Neck Cancer, Immunotherapy as 1st-Line Treatment Prolongs Survival

ESMO 2018 Congressreported results of the clinical trial called KEYNOTE-048, showing that pembrolizumab (Keytruda) immunotherapy improves survival in patients with recurrent or metastatic head and neck cancer.

For metastatic or recurrent head and neck cancer, the current standard treatmentis platinum-based chemotherapy [cisplatin or carboplatin with 5-fluorouracil (5-FU)] plus the EGFR inhibitor cetuximab.

For head and neck cancer that has recurred or is at stage 4, approximately % 35 of patients respond to standard treatment, providing a median survival of more than ten months. Previously, pembrolizumab in August 2016 and nivolumab (Opdivo) in November 2016 received FDA approval for 2nd-line treatment of recurrent or metastatic head and neck cancers. The study discussed in this article concerns using pembrolizumab as initial treatment.

Related Topics:

Study Details

The phase III KEYNOTE-048 study investigated whether the anti-PD-1 monoclonal antibody pembrolizumab improved disease control with treatment and prolonged survival compared with standard treatment. KEYNOTE-048 includes patients with head and neck cancer who had not previously received chemotherapy or biological therapy for recurrent or metastatic disease.

Patients were randomly assigned in equal proportions to 3 groups:

  1. standard treatment: platinum-based chemotherapy (cisplatin or carboplatin with 5-FU) and cetuximab (control group)
  2. pembrolizumab alone
  3. a new combination of pembrolizumab plus platinum-based chemotherapy. Results relating to the immunotherapy pembrolizumab compared with standard treatment were presented for all patients, regardless of PD-L1 positivity.

Study Results

In the first comparison, 301 patients received pembrolizumab and 300 received standard treatment; mean follow-up was 11.7 months for pembrolizumab and 10.7 months for the chemotherapy arm. In PD-L1-positive patients (combined positive score [CPS]> 20);

  • Overall survival was 14.9 months with pembrolizumab versus 10.7 months with standard treatment.
  • In this patient group, immunotherapy reduced the risk of death by % 39.
  • An objective response was seen in % 23.3 of patients receiving pembrolizumab and % 36.1 receiving standard treatment.
  • Median response duration was 4.5 months with standard treatment versus 20.9 months with pembrolizumab.
  • There was no difference between the groups in median progression-free survival (the time disease is kept under control with treatment).

According to this study's results, patients with PD-L1-positive recurrent or metastatic head and neck cancer live longer when they begin initial treatment with pembrolizumab.

In patients with lower PD-L1 positivity (CPS> 1);

  • Overall survival again favored pembrolizumab (12.3 versus 10.3 months).
  • An objective treatment response was seen in % 19.1 of those receiving pembrolizumab and % 34.9 of those receiving standard chemotherapy.
  • Median response duration was longer with standard pembrolizumab (20.9 versus 4.5 months)
  • There was no difference in progression-free survival between the groups (HR 1.16,% 95 CI 0.75-1.29).

-In the second comparison, 281 patients received the new combination of pembrolizumab and platinum-based chemotherapy, and 278 received standard treatment; median follow-up was 13.0 and 10.7 months, respectively.

  • Overall survival was 13 months with the immunotherapy plus chemotherapy combination versus 10.7 months with standard treatment.
  • The immunotherapy-containing regimen reduced the risk of death by % 23.
  • Response rates were % 35.6 for the pembrolizumab combination and % 36.3 for standard treatment.
  • There was no difference in progression-free survival between the groups.

Side effects in the three treatment groups were similar to typical immunotherapy side effects. Pembrolizumab alone had fewer side effects than standard treatment. Pembrolizumab combined with chemotherapy and standard treatment had similar toxicity.

Conclusion

In this study, compared with standard treatment, pembrolizumab alone had a lower response rate and numerically shorter progression-free survival, yet significantly longer overall survival, which is noteworthy. Pembrolizumab appears to prolong life even when the cancer continues to grow, suggesting that it should be first-line treatment for recurrent and metastatic head and neck cancer. This clinical trial is also the first study in the past ten years to show superior survival over standard treatment in the first-line setting. Whether pembrolizumab should be given alone or with chemotherapy may depend on PD-L1 positivity, and analyses are underway to answer this question.

Sources

Barbara Burtness ve ark.
First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): interim results from the phase 3 KEYNOTE-048 study.
ESMO 2018, Abstract LBA8_PR

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

For Recurrent or Stage 4 Head and Neck Cancer, Immunotherapy as 1st-Line Treatment Prolongs Survival

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy